Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD
Author
Abstract
Suggested Citation
DOI: 10.1007/s10198-013-0484-1
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
References listed on IDEAS
- Philipson Tomas J & Jena Anupam B, 2006.
"Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs,"
Forum for Health Economics & Policy, De Gruyter, vol. 9(2), pages 1-33, January.
- Tomas J. Philipson & Anupam B. Jena, 2005. "Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS Drugs," NBER Working Papers 11810, National Bureau of Economic Research, Inc.
- Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010.
"An economic evaluation of the war on cancer,"
Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
- Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman, 2009. "An Economic Evaluation of the War on Cancer," NBER Working Papers 15574, National Bureau of Economic Research, Inc.
- Craig L. Garthwaite, 2012. "The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors," American Economic Journal: Applied Economics, American Economic Association, vol. 4(3), pages 116-137, July.
- Jena, Anupam B. & Philipson, Tomas J., 2008. "Cost-effectiveness analysis and innovation," Journal of Health Economics, Elsevier, vol. 27(5), pages 1224-1236, September.
- Rodrigo Refoios Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2013. "The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies," PharmacoEconomics, Springer, vol. 31(5), pages 445-454, May.
- Peter Lindgren & Bengt Jönsson, 2012. "Cost–effectiveness of statins revisited: lessons learned about the value of innovation," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(4), pages 445-450, August.
- Refoios Camejo, Rodrigo & McGrath, Clare & Herings, Ron, 2011. "A dynamic perspective on pharmaceutical competition, drug development and cost effectiveness," Health Policy, Elsevier, vol. 100(1), pages 18-24, April.
- Jena, Anupam B. & Philipson, Tomas J., 2013.
"Endogenous cost-effectiveness analysis and health care technology adoption,"
Journal of Health Economics, Elsevier, vol. 32(1), pages 172-180.
- Anupam Jena & Tomas Philipson, 2009. "Endogenous Cost-Effectiveness Analysis in Health Care Technology Adoption," NBER Working Papers 15032, National Bureau of Economic Research, Inc.
- Thomas A. Abbott & John A. Vernon, 2005. "The Cost of US Pharmaceutical Price Reductions: A Financial Simulation Model of R&D Decisions," NBER Working Papers 11114, National Bureau of Economic Research, Inc.
- David Reiffen & Michael R. Ward, 2005. "Generic Drug Industry Dynamics," The Review of Economics and Statistics, MIT Press, vol. 87(1), pages 37-49, February.
Citations
Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
Cited by:
- Beth Woods & Aimée Fox & Mark Sculpher & Karl Claxton, 2021. "Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems," Health Economics, John Wiley & Sons, Ltd., vol. 30(11), pages 2649-2666, November.
- Patrícia Véras Marrone & Fabio Rampazzo Mathias & Wanderley Marques Bernardo & Marina Feliciano Orlandini & Maria Carolina Andrade Serafim & Maria Lídia Rebello Pinho Dias Scoton & Juliano Marçal Lope, 2023. "Decision Criteria for Partial Nationalization of Pharmaceutical Supply Chain: A Scoping Review," Economies, MDPI, vol. 11(1), pages 1-21, January.
Most related items
These are the items that most often cite the same works as this one and are cited by the same works as this one.- Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
- Eric Budish & Benjamin N. Roin & Heidi Williams, 2015.
"Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials,"
American Economic Review, American Economic Association, vol. 105(7), pages 2044-2085, July.
- Eric Budish & Benjamin N. Roin & Heidi Williams, 2013. "Do firms underinvest in long-term research? Evidence from cancer clinical trials," NBER Working Papers 19430, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Sachin Kamal-Bahl & Anupam B. Jena, 2017. "Defining Value: The Need for a Longer, Broader View," PharmacoEconomics, Springer, vol. 35(7), pages 669-672, July.
- Basu, Anirban & Jena, Anupam B. & Philipson, Tomas J., 2011.
"The impact of comparative effectiveness research on health and health care spending,"
Journal of Health Economics, Elsevier, vol. 30(4), pages 695-706, July.
- Anirban Basu & Tomas J. Philipson, 2010. "The Impact of Comparative Effectiveness Research on Health and Health Care Spending," NBER Working Papers 15633, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Gary Becker & Dana Goldman & Kevin M. Murphy, 2010.
"Terminal Care and The Value of Life Near Its End,"
NBER Working Papers
15649, National Bureau of Economic Research, Inc.
- Tomas Philipson & Gary S. Becker & Dana Goldman & Kevin Murphy, 2010. "Terminal Care and the Value of Life Near Its End," Working Papers 2010-005, Becker Friedman Institute for Research In Economics.
- Boone, Jan, 2013.
"Does the market choose optimal health insurance coverage?,"
CEPR Discussion Papers
9420, C.E.P.R. Discussion Papers.
- Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Discussion Paper 2013-008, Tilburg University, Tilburg Law and Economic Center.
- Boone, J., 2013. "Does the Market Choose Optimal Health Insurance Coverage," Other publications TiSEM f7691fbf-f770-4714-b1b4-1, Tilburg University, School of Economics and Management.
- Amitabh Chandra & Jonathan S. Skinner, 2011. "Technology Growth and Expenditure Growth in Health Care," NBER Working Papers 16953, National Bureau of Economic Research, Inc.
- Rodrigo Refoios Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2013. "The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies," PharmacoEconomics, Springer, vol. 31(5), pages 445-454, May.
- Lichtenberg Frank R., 2010. "Pharmaceutical Price Discrimination and Social Welfare," Capitalism and Society, De Gruyter, vol. 5(1), pages 1-32, July.
- Thornton Snider Julia & Romley John A. & Vogt William B. & Philipson Tomas J., 2012. "The Option Value of Innovation," Forum for Health Economics & Policy, De Gruyter, vol. 15(2), pages 1-19, April.
- Anupam B. Jena & Stéphane Mechoulan & Tomas J. Philipson, 2010. "Altruism and Innovation in Health Care," Journal of Law and Economics, University of Chicago Press, vol. 53(3), pages 497-518.
- Lakdawalla, Darius & Malani, Anup & Reif, Julian, 2017.
"The insurance value of medical innovation,"
Journal of Public Economics, Elsevier, vol. 145(C), pages 94-102.
- Darius Lakdawalla & Anup Malani & Julian Reif, 2015. "The Insurance Value of Medical Innovation," NBER Working Papers 21015, National Bureau of Economic Research, Inc.
- Brekke, Kurt R. & Dalen, Dag Morten & Straume, Odd Rune, 2023. "The price of cost-effectiveness thresholds under therapeutic competition in pharmaceutical markets," Journal of Health Economics, Elsevier, vol. 90(C).
- Frank R. Lichtenberg, 2014.
"Has Medical Innovation Reduced Cancer Mortality?,"
CESifo Economic Studies, CESifo Group, vol. 60(1), pages 135-177.
- Frank R. Lichtenberg, 2010. "Has medical innovation reduced cancer mortality?," NBER Working Papers 15880, National Bureau of Economic Research, Inc.
- Mikael Svensson & Fredrik Nilsson & Karl Arnberg, 2015. "Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness," PharmacoEconomics, Springer, vol. 33(11), pages 1229-1236, November.
- John Vernon & Robert Goldberg & Joseph Golec, 2009. "Economic Evaluation and Cost-Effectiveness Thresholds," PharmacoEconomics, Springer, vol. 27(10), pages 797-806, October.
- Jeon, Sung-Hee & Pohl, R. Vincent, 2019.
"Medical innovation, education, and labor market outcomes of cancer patients,"
Journal of Health Economics, Elsevier, vol. 68(C).
- Sung-Hee Jeon & Vincent Pohl, 2019. "Medical Innovation, Education, and Labor Market Outcomes of Cancer Patients," Upjohn Working Papers 19-306, W.E. Upjohn Institute for Employment Research.
- Bergman , Mats A. & Granlund, David & Rudholm, Niklas, 2016. "Squeezing the last drop out of your suppliers: an empirical study of market-based purchasing policies for generic pharmaceuticals," Umeå Economic Studies 921, Umeå University, Department of Economics.
- Hostenkamp, Gisela, 2013. "Do follow-on therapeutic substitutes induce price competition between hospital medicines? Evidence from the Danish hospital sector," Health Policy, Elsevier, vol. 111(1), pages 68-77.
More about this item
Keywords
Consumer surplus; Producer surplus; Dynamic efficiency; Research and development; Pharmaceutical innovation; Pharmaceutical policy; H51; I11; I18;All these keywords.
JEL classification:
- H51 - Public Economics - - National Government Expenditures and Related Policies - - - Government Expenditures and Health
- I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
- I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health
Statistics
Access and download statisticsCorrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:15:y:2014:i:4:p:439-445. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .
Please note that corrections may take a couple of weeks to filter through the various RePEc services.